TY - JOUR
T1 - Essential metabolism required for T and B lymphocyte functions
T2 - an update
AU - Diniz, Vinicius Leonardo Sousa
AU - Alvares-Saraiva, Anuska Marcelino
AU - Serdan, Tamires Duarte Afonso
AU - Dos Santos-Oliveira, Laiane Cristina
AU - Cruzat, Vinicius
AU - Lobato, Tiago Bertola
AU - Manoel, Richelieau
AU - Alecrim, Amanda Lins
AU - Machado, Otavio Augusto
AU - Hirabara, Sandro M.
AU - Masi, Laureane Nunes
AU - Pithon-Curi, Tania Cristina
AU - Curi, Rui
AU - Gorjão, Renata
AU - Newsholme, Philip
N1 - Publisher Copyright:
© 2023 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.
PY - 2023/5/31
Y1 - 2023/5/31
N2 - Lymphocytes act as regulatory and effector cells in inflammation and infection situations. A metabolic switch towards glycolytic metabolism predominance occurs during T lymphocyte differentiation to inflammatory phenotypes (Th1 and Th17 cells). Maturation of T regulatory cells, however, may require activation of oxidative pathways. Metabolic transitions also occur in different maturation stages and activation of B lymphocytes. Under activation, B lymphocytes undergo cell growth and proliferation, associated with increased macromolecule synthesis. The B lymphocyte response to an antigen challenge requires an increased adenosine triphosphate (ATP) supply derived mainly through glycolytic metabolism. After stimulation, B lymphocytes increase glucose uptake, but they do not accumulate glycolytic intermediates, probably due to an increase in various metabolic pathway 'end product' formation. Activated B lymphocytes are associated with increased utilization of pyrimidines and purines for RNA synthesis and fatty acid oxidation. The generation of plasmablasts and plasma cells from B lymphocytes is crucial for antibody production. Antibody production and secretion require increased glucose consumption since 90% of consumed glucose is needed for antibody glycosylation. This review describes critical aspects of lymphocyte metabolism and functional interplay during activation. We discuss the primary fuels for the metabolism of lymphocytes and the particularities of T and B cell metabolism, including the differentiation of lymphocytes, stages of development of B cells, and the production of antibodies.
AB - Lymphocytes act as regulatory and effector cells in inflammation and infection situations. A metabolic switch towards glycolytic metabolism predominance occurs during T lymphocyte differentiation to inflammatory phenotypes (Th1 and Th17 cells). Maturation of T regulatory cells, however, may require activation of oxidative pathways. Metabolic transitions also occur in different maturation stages and activation of B lymphocytes. Under activation, B lymphocytes undergo cell growth and proliferation, associated with increased macromolecule synthesis. The B lymphocyte response to an antigen challenge requires an increased adenosine triphosphate (ATP) supply derived mainly through glycolytic metabolism. After stimulation, B lymphocytes increase glucose uptake, but they do not accumulate glycolytic intermediates, probably due to an increase in various metabolic pathway 'end product' formation. Activated B lymphocytes are associated with increased utilization of pyrimidines and purines for RNA synthesis and fatty acid oxidation. The generation of plasmablasts and plasma cells from B lymphocytes is crucial for antibody production. Antibody production and secretion require increased glucose consumption since 90% of consumed glucose is needed for antibody glycosylation. This review describes critical aspects of lymphocyte metabolism and functional interplay during activation. We discuss the primary fuels for the metabolism of lymphocytes and the particularities of T and B cell metabolism, including the differentiation of lymphocytes, stages of development of B cells, and the production of antibodies.
KW - Antibody production
KW - B Cell
KW - Glucose
KW - Glutamine
KW - Immunometabolism
KW - Leucocyte
UR - http://www.scopus.com/inward/record.url?scp=85160023524&partnerID=8YFLogxK
U2 - 10.1042/CS20220869
DO - 10.1042/CS20220869
M3 - Review article
C2 - 37219940
AN - SCOPUS:85160023524
SN - 0143-5221
VL - 137
SP - 807
EP - 821
JO - Clinical science (London, England : 1979)
JF - Clinical science (London, England : 1979)
IS - 10
ER -